Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 3.45Pfizer Ltd presents a mixed financial profile. Its key strength lies in its financial stability, characterized by a very low reliance on debt, which reduces long-term risk. Operationally, it shows some efficiency in managing inventory and collecting payments quickly. However, the company faces significant challenges in other critical areas. Its ability to cover short-term bills appears constrained. Furthermore, there are considerable weaknesses in profitability and growth, with sales and earnings lagging. This indicates difficulty in converting revenue into profit and expanding its business. The future outlook depends on its ability to address these core operational and profitability issues. While its low-debt structure provides a stable base, the lack of growth and poor returns are significant concerns.
Health Score : 3.45Pfizer Ltd presents a mixed financial profile. Its key strength lies in its financial stability, characterized by a very low reliance on debt, which reduces long-term risk. Operationally, it shows some efficiency in managing inventory and collecting payments quickly. However, the company faces significant challenges in other critical areas. Its ability to cover short-term bills appears constrained. Furthermore, there are considerable weaknesses in profitability and growth, with sales and earnings lagging. This indicates difficulty in converting revenue into profit and expanding its business. The future outlook depends on its ability to address these core operational and profitability issues. While its low-debt structure provides a stable base, the lack of growth and poor returns are significant concerns.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
29.55
Industry Median
35.50
Small Cap Median
24.51
P/E RATIO
46.48
P/B RATIO
15.45
Industry Median
11.94
Small Cap Median
8.44
P/S RATIO
31.45
Industry Median
7.76
Small Cap Median
3.65
Others
PEG RATIO
0.00
EV/EBITDA RATIO
48.32
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹4665.9 as on Sep 1, 2026.
Growth Score : 2.00The company's growth prospects appear weak across all key financial indicators. It is experiencing a lack of growth, or even a decline, in its revenues, operating profits, and net income. Additionally, its asset base is not expanding. This stagnation suggests that the company is facing significant headwinds, either from market conditions or internal operational issues, and is struggling to expand its business. This poses a long-term risk for its sustainability.
Revenue Growth RatePoorOperating Profit Growth RatePoorEarnings Per Share (EPS) GrowthPoorAsset Growth RatePoorNet Income Growth RatePoorRevenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 54.51 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 2 | Gland Pharma Ltd | 7.91 | 46.11 | Overvalued | 1630.00 | 78.78 | 1027.00 |
| 3 | Neuland Laboratories Ltd | 7.84 | 81.16 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 4 | Granules India Ltd | 7.73 | 34.87 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 5 | Ajanta Pharma Ltd | 7.72 | 41.47 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 6 | Alembic Pharmaceuticals Ltd | 7.60 | 24.58 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 7 | Emcure Pharmaceuticals Ltd | 7.40 | 37.86 | Neutral | 1865.00 | 38.64 | 941.00 |
| 8 | Syngene International Ltd | 7.16 | 51.15 | Neutral | 918.00 | 7.55 | 317.00 |
| 9 | ERIS Lifesciences Ltd | 7.15 | 29.07 | Neutral | 1120.00 | 17.61 | 648.00 |
| 10 | Piramal Pharma Ltd | 5.83 | -87.02 | Neutral | 922.00 | 5.26 | -326.00 |
| 11 | Jubilant Pharmova Ltd | 5.71 | 36.27 | Neutral | 1260.00 | 1.25 | 398.00 |
| 12 | Natco Pharma Ltd | 5.69 | 10.72 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 13 | Wockhardt Ltd | 5.07 | 141.16 | Neutral | 652.00 | 19.51 | 199.00 |
| 14 | Pfizer Ltd | 3.45 | 46.48 | Neutral | -82.00 | 157.92 | 300.00 |
| 15 | Procter & Gamble Health Ltd | 3.45 | 29.33 | Neutral | 466.00 | 215.00 | 357.00 |
| 16 | Sanofi India Ltd | 3.45 | 17.56 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Pfizer Ltd is a prominent Indian pharmaceutical company, majority-owned by global pharmaceutical giant Pfizer Inc. It manufactures, markets, and distributes a wide range of pharmaceutical products across key therapeutic areas, including vaccines, specialty care, and internal medicine, contributing significantly to healthcare access in India.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Pfizer Ltd's P/E ratio (TTM) is 29.55, compared to the industry median of 35.50 and large cap median of 24.51.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Pfizer Ltd's P/B ratio is 15.45, compared to the industry median of 11.94 and large cap median of 8.44.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Pfizer Ltd's P/S ratio is 31.45, compared to the industry median of 7.76 and large cap median of 3.65.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Pfizer Ltd's PEG ratio is -0.73.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Pfizer Ltd's EV/EBITDA ratio is 48.32.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Pfizer Ltd's ROE is N/A.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Pfizer Ltd's ROA is N/A.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Pfizer Ltd's ROCE is N/A.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Pfizer Ltd's operating margin is N/A.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Pfizer Ltd's net margin is N/A.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Pfizer Ltd's current ratio is N/A.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Pfizer Ltd's debt-to-equity ratio is N/A.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Pfizer Ltd's interest coverage ratio is N/A.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Pfizer Ltd's DPS is ₹35.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Pfizer Ltd's EPS is N/A.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹4665.90. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1950
Headquarters: Mumbai, Maharashtra
Core Offerings: Vaccines, Oncology, Specialty Care, Internal Medicine, Inflammation & Immunology
Stock Listing: NSE (PFIZER), BSE (500680)
Promoter: Pfizer Inc.
Pfizer Limited was incorporated in India in 1950 as Pfizer Private Limited. In 1951, it launched the broad-spectrum antibiotic Terramycin, marking a significant entry into the Indian market. The company established manufacturing facilities in India over the years, steadily expanding its product portfolio and market presence. It transitioned into a public limited company, with its shares subsequently listed on Indian stock exchanges. Throughout its history, Pfizer Ltd has been a key player in the Indian pharmaceutical sector, leveraging its parent company's global research and development to introduce innovative medicines and improve public health in India.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceuticals | 100% | N/A (Company-wide EBITDA) |
Pharmaceuticals: Pfizer Ltd operates exclusively in the pharmaceutical sector, focusing on the manufacturing, marketing, and distribution of a diverse portfolio of prescription medicines and vaccines.
The company's product categories include a range of therapeutic areas such as Vaccines (e.g., Prevenar 13), Oncology (e.g., Ibrance), Specialty Care (e.g., Xeljanz), Internal Medicine, and Anti-infectives, addressing significant health challenges.
Operations encompass domestic sales, exports, and contract manufacturing activities, supported by a robust sales and distribution network across India, ensuring broad access to its products.
Pradip Shah (Chairman & Independent Director): A seasoned professional with extensive experience in financial services and business strategy, providing critical guidance on corporate governance. Meenakshi Nevatia (Managing Director): Appointed in 2023, she brings over 25 years of diverse experience in the healthcare industry, having held leadership positions across India, South Asia, and Europe.
No major subsidiaries reported.
In August 2023, the company declared a final dividend of ₹35.00 per share and a special dividend of ₹20.00 per share for the financial year 2022-23. In 2021, the company completed the divestiture of its Upjohn business, aligning with its global strategic transformation.
The Pfizer Ltd share price today is ₹4665.90 on NSE (PFIZER), as of 26 Sept 2026.
As of 25 Sept 2026, Pfizer Ltd share price is ₹4665.90, with previous close ₹4665.90. Today's range is ₹4665.90 to ₹4665.90. The 52-week range is ₹3955.50 to ₹5257.
As of today, Pfizer Ltd's market cap is ₹21,323.16 crore (Large Cap).
Pfizer Ltd's current P/E ratio is 29.55, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 34.
Pfizer Ltd's current P/B ratio is 15.45.
Pfizer Ltd's current dividend yield is 0.75%. Last dividend of ₹35.00 per share was declared on 18-Aug-2023.
Pfizer Ltd's EPS (TTM) is ₹N/A.
Pfizer Ltd is a prominent Indian pharmaceutical company, majority-owned by global pharmaceutical giant Pfizer Inc. It manufactures, markets, and distributes a wide range of pharmaceutical products across key therapeutic areas, including vaccines, specialty care, and internal medicine, contributing significantly to healthcare access in India.
Pfizer Ltd is promoted by Pfizer Inc., holding 63.92% as of 25 Sept 2026.
Pfizer Ltd is listed on NSE (PFIZER) and BSE (500680). Its next quarterly results are expected on May 2024.
Capital Expenditures (CapEx)
Capital Efficiency & Returns
